Equities research analysts expect Repligen Co. (NASDAQ:RGEN) to post $0.20 earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for Repligen’s earnings, with estimates ranging from $0.18 to $0.21. Repligen posted earnings per share of $0.17 in the same quarter last year, which would indicate a positive year over year growth rate of 17.6%. The business is scheduled to issue its next quarterly earnings report on Tuesday, May 14th.
On average, analysts expect that Repligen will report full year earnings of $0.85 per share for the current year, with EPS estimates ranging from $0.81 to $0.92. For the next financial year, analysts forecast that the company will post earnings of $0.97 per share, with EPS estimates ranging from $0.95 to $1.02. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Repligen.
Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 21st. The biotechnology company reported $0.21 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.21. Repligen had a net margin of 8.56% and a return on equity of 5.55%. The firm had revenue of $51.90 million during the quarter, compared to analysts’ expectations of $50.27 million. During the same period last year, the firm posted $0.20 earnings per share. The firm’s revenue for the quarter was up 24.8% compared to the same quarter last year.
Shares of NASDAQ:RGEN traded up $3.28 during trading on Tuesday, reaching $62.80. 488,770 shares of the company traded hands, compared to its average volume of 267,715. The firm has a market capitalization of $2.58 billion, a P/E ratio of 86.03, a price-to-earnings-growth ratio of 4.01 and a beta of 1.04. Repligen has a 1-year low of $33.51 and a 1-year high of $70.50.
Several institutional investors have recently added to or reduced their stakes in RGEN. Bank of America Corp DE raised its holdings in shares of Repligen by 22.2% during the 2nd quarter. Bank of America Corp DE now owns 98,716 shares of the biotechnology company’s stock valued at $4,644,000 after purchasing an additional 17,923 shares in the last quarter. Millennium Management LLC bought a new position in shares of Repligen during the 2nd quarter valued at $1,628,000. Bank of New York Mellon Corp raised its holdings in Repligen by 2.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 498,849 shares of the biotechnology company’s stock worth $23,466,000 after acquiring an additional 14,041 shares during the period. Aperio Group LLC raised its holdings in Repligen by 5.5% in the 3rd quarter. Aperio Group LLC now owns 44,515 shares of the biotechnology company’s stock worth $2,469,000 after acquiring an additional 2,319 shares during the period. Finally, Seven Eight Capital LP bought a new position in Repligen in the 3rd quarter worth $217,000. Institutional investors and hedge funds own 90.51% of the company’s stock.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.